Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › FDA Approves Bristol Myers Squibb's CAR T-cell Therapy Breyanzi for Large B-cell Lymphoma

FDA Approves Bristol Myers Squibb's CAR T-cell Therapy Breyanzi for Large B-cell Lymphoma

Feb 05, 2021
|
staff reporter

NEW YORK – The US Food and Drug Administration on Friday approved lisocabtagene maraleucel (Bristol Myers Squibb's Breyanzi) as a treatment for relapsed or refractory large B-cell lymphoma.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. Roche Withdraws Tecentriq for Bladder Cancer After FDA Accelerated Approval Review

  2. UK's NICE Does Not Recommend Lynparza for BRCA-Mutated Prostate Cancer

  3. FDA Approves Gilead's CAR T-cell Therapy Yescarta for Follicular Lymphoma

  4. FDA Expands Approval of Pfizer's Lorbrena to First-Line ALK-Positive NSCLC; Approves Roche CDx

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.